Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Accured Expenses (2016 - 2025)

Mimedx's Change in Accured Expenses history spans 15 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 134.29% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $2.4 million, down 18.13%, while the annual FY2025 figure was $2.4 million, 18.13% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.4 million at Mimedx, down from $4.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.0 million in Q3 2022 and bottomed at -$6.0 million in Q2 2022.
  • The 5-year median for Change in Accured Expenses is -$51500.0 (2021), against an average of $298850.0.
  • The largest annual shift saw Change in Accured Expenses tumbled 19740.0% in 2022 before it skyrocketed 672.61% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$3.2 million in 2021, then skyrocketed by 120.19% to $655000.0 in 2022, then dropped by 16.95% to $544000.0 in 2023, then surged by 672.61% to $4.2 million in 2024, then plummeted by 134.29% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Change in Accured Expenses are -$1.4 million (Q4 2025), $4.6 million (Q3 2025), and -$718000.0 (Q2 2025).